AIM
ARGS

Acrospire Investment Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Acrospire Investment Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-90
Closed -$9K – 2744
2016
Q4 		$9K Sell
90
-15
-14% -$1.4K ﹤0.01% 1981
2016
Q3 		$10K Buy
+105
New +$11K 0.01% 1720

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return

Acrospire Investment Management's ARGS Position: Q1 2017 in Review

Acrospire Investment Management sold out of Argos Therapeutics, Inc. (ARGS) in Q1 2017, closing a stake of 90 shares — an estimated $9K sold.

Acrospire Investment Management first reported a position in ARGS in Q3 2016 and held it in 2 quarters. The position peaked at $10K in Q3 2016. 43 funds tracked by Wall St. Rank hold ARGS as of Q1 2017.

  • Acrospire Investment Management reported no remaining Argos Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 90 Argos Therapeutics, Inc. shares in Q1 2017, an estimated $9K.
  • Acrospire Investment Management first reported a position in Argos Therapeutics, Inc. in Q3 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Argos Therapeutics, Inc. position peaked at $10K in Q3 2016.
  • 43 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.